POSB73 Cost-Minimization Analysis for Subcutaneous Daratumumab in the Treatment of Multiple Myeloma in Italy

Abstract

Daratumumab administered via an intravenous infusion (dara-IV) is currently approved for the treatment of patients with multiple myeloma, both newly diagnosed (NDMM) and relapsed/refractory (RRMM). A daratumumab formulation for subcutaneous administration (dara-SC) was developed with the goal of shortening treatment duration without compromising safety and efficacy. Dara-SC was licensed in 2020 and is expected to be reimbursed in the Italian setting for the same indications as dara-IV. A cost-minimization model (CMM) was developed to evaluate the economic implications of using dara-SC instead of dara-IV in Italy.